Moderna, COVID-19
Shares of Moderna Inc. MRNA slipped 2.63% to $68.02 Thursday, on what proved to be an all-around favorable trading session ...
Investor's Business Daily on MSN5d
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D DayModerna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have ...
Shares of Moderna Inc. MRNA slipped 3.43% to $65.69 Friday, on what proved to be an all-around mixed trading session for the ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Moderna 's ( MRNA -2.63%) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback